Do More With Reuters
Partner Services

Novo Nordisk's Victoza gets EU market green light

Fri Jul 3, 2009 2:34pm IST
 
Email | Print | | Single Page
[-] Text [+]

COPENHAGEN, July 3 (Reuters) - Danish pharmaceuticals group Novo Nordisk's (NOVOb.CO: Quote, Profile, Research) diabetes treatment Victoza has won European Commission approval for marketing across the EU, the company said on Friday.

"The European Commission has granted marketing authorisation for Victoza for the treatment of type 2 diabetes in adults," Novo Nordisk said in a statement, calling it an "important milestone."

The company will launch Victoza in the UK, Germany and Denmark this summer and in other European markets in the second half of 2009 and throughout 2010, it said.

"The marketing approval in Europe does not change Novo Nordisk's expectations for the company's financial results for 2009," it added.

Britain's Prime Minister Gordon Brown speaks, as finance minister Alistair Darling listens at the G20 Finance Ministers meeting in St. Andrews, Scotland. REUTERS/POOL New
UK joins G20 push for world levy on banks

Britain threw its weight behind proposals to impose a global levy on banks to fund future bailouts and called on the G20 to work toward a $100 billion deal to meet the cost of climate change.  Full Article | Full Coverage 

Market Update

  • IndiaIndia
  • USUS
  • UKUK
  • Asia
  • Most Actives

column

Nipun Mehta
Nipun Mehta, SG Private Banking
India - planning the road to recovery

There needs to be an acceptable balance created between education & healthcare and infrastructure spend.  Full Article 

SHOWCASE

Robot Asimo

Snapshots of Honda Motor's humanoid robot Asimo  Slideshow 

 
Marketing Strategy
Marketing Strategy

Companies are now using direct marketing methods to sell their products.  Full Article 

 
Out of Woods?
Out of the Woods?

Analysis - CIT's bankruptcy exit fraught with uncertainty  Full Article 

 
Exit Plans
Exit Plans

Factbox - Stimulus exit plans for Asia-Pacific's big 5 economies  Full Article